News | January 07, 2026
Merck completes acquisition of Cidara Therapeutics
Cidara will become a wholly owned subsidiary of Merck and the common stock of Cidara will no longer be listed or traded on the Nasdaq Global Market
Cidara will become a wholly owned subsidiary of Merck and the common stock of Cidara will no longer be listed or traded on the Nasdaq Global Market
The SNS records neural activity from 60 channels across four brain regions—far exceeding current commercial devices
The decision positions Yartemlea as the first and only approved inhibitor of the lectin pathway of complement
Leaders from science, policy, industry, and investment came together in New Delhi to examine how alignment across the biotechnology value chain can turn innovation into outcomes at scale
The trials did not show a statistically significant reduction in annualized clinical fracture rates compared to placebo or bisphosphonates
Motiva, SmoothSilk, Round and Ergonomix implants represent the latest in plastic surgery innovation
The surgical team used LD Flap Reconstruction, a specialised technique that rebuilt elbow strength and movement
The acquisition adds HLD-0915, a once-daily oral therapy for prostate cancer, to Johnson & Johnson’s nearly 20-year legacy of innovation in the disease
Lucid-MS represents a potential breakthrough in the treatment of multiple sclerosis
The study focused on patients without actionable genomic alterations whose disease had progressed after prior immunotherapy and platinum-based chemotherapy
Subscribe To Our Newsletter & Stay Updated
